Drug Approval | May 12, 2022
USFDA approves Lilly and Incyte's Olumiant to treat hospitalised patients with Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible
Abbott's multiplex test runs on its most advanced molecular PCR platform, the Alinity m system, which provides fast results in high volumes – detecting four infections simultaneously
While Pregabalin will be manufactured at the Aurangabad facility, Iloperidone will be manufactured at the Goa facility
The drug will be manufactured at the group's formulation facility at SEZ, Ahmedabad
According to the National Institutes of Health, more than six million Americans, most age 65 or older, may have dementia caused by Alzheimer's disease, a brain disorder known to slowly destroy memory and thinking skills
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
Subscribe To Our Newsletter & Stay Updated
